The EZH2 inhibitor tazemetostat mitigates HIV immune evasion, reduces reservoir formation, and promotes durable CD8+ T-cell revitalization

Andrea Gramatica,Itzayana G Miller,Adam R Ward,Farzana Khan,Tyler J Kemmer,Jared Weiler,Tan T Huynh,Paul Zumbo,Andrew P Kurland,Louise Leyre,Yanqin Ren,Thais Klevorn,Dennis C Copertino,Uche Chukwukere,Callie Levinger,Thomas R Dilling,Noemi L Linden,Nathan L Board,Emma Falling Iversen,Sandra Terry,Talia M Mota,Seden Bedir,Kiera L Clayton,Alberto Bosque,Lynsay MacLaren Ehui,Colin M Kovacs,Doron Betel,Jeffrey R Johnson,Mirko Paiardini,Ali Danesh,R. Brad Jones
DOI: https://doi.org/10.1101/2024.10.11.617869
2024-10-15
Abstract:Persistent HIV reservoirs in CD4+ T-cells pose a barrier to curing HIV infection. We identified overexpression of enhancer of zeste homolog 2 (EZH2) in HIV-infected CD4+ T-cells that survive cytotoxic T lymphocyte (CTL) exposure, suggesting a mechanism of CTL resistance. Inhibition of EZH2 with the FDA-approved drug tazemetostat increased surface expression of major histocompatibility complex class I (MHC-I) on CD4+ T-cells, counterbalancing HIV Nef-mediated MHC-I downregulation. This improved CTL-mediated elimination of HIV-infected cells and suppressed viral replication in vitro. In a participant-derived xenograft mouse model, tazemetostat elevated MHC-I and the pro-apoptotic protein BIM in CD4+ T-cells, facilitating CD8+ T-cell-mediated reductions of HIV reservoir seeding. Additionally, tazemetostat promoted sustained skewing of CD8+ T-cells toward less differentiated and exhausted phenotypes. Our findings reveal EZH2 overexpression as a novel mechanism of CTL resistance and support the clinical evaluation of tazemetostat to enhance clearance of HIV reservoirs and improve CD8+ T-cell function.
Immunology
What problem does this paper attempt to address?